_PRIVATE_LIMITED.webp)
First Time Us Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 4.37 Cr
as on 15-11-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 42.33%
(FY 2023)
- Profit 661.23%
(FY 2023)
- Ebitda 637.37%
(FY 2023)
- Net Worth 29.01%
(FY 2023)
- Total Assets 39.46%
(FY 2023)
About First Time Us Pharmaceuticals (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 4.37 Cr, as per Ministry of Corporate Affairs (MCA) records.
Manesh Dixit, Priyanka Misar, and Vibhor Misar serve as directors at the Company.
- CIN/LLPIN
U74999MH2013FTC244256
- Company No.
244256
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
10 Jun 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNavi Mumbai, Maharashtra
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at First Time Us Pharmaceuticals (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manesh Dixit  | Director | 10-Jun-2013 | Current |
Priyanka Misar  | Director | 10-Jun-2013 | Current |
| Vibhor Misar | Director | 18-Dec-2013 | Current |
Financial Performance of First Time Us Pharmaceuticals (India).
First Time Us Pharmaceuticals (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 42.33% increase. The company also saw a substantial improvement in profitability, with a 661.23% increase in profit. The company's net worth Soared by an impressive increase of 29.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of First Time Us Pharmaceuticals (India)?
In 2023, First Time Us Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at First Time Us Pharmaceuticals (India)?
First Time Us Pharmaceuticals (India) has a workforce of 48 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of First Time Us Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped First Time Us Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
